Development and Validation of a High Sensitivity Assay for Measuring p217+tau in Cerebrospinal Fluid

Manuscript Number: 

20-0463R1

Author(s): 
Wendy Galpern, Hartmuth C. Kolb, Marc Mercken, Setareh H. Moghadam, Randy Slemmon, Hong Sun, Clara Theunis, Gallen Triana-Baltzer, Kristof Van Kolen

Disclosures

Wendy Galpern

  • Equity:
    I am a full time employee of Janssen/Johnson and Johnson and have Johnson and Johnson stock/stock options.
    Sponsors:
    I am a full time employee of Janssen/Johnson and Johnson

Hartmuth C. Kolb

  • Equity:
    I am employed by J&J / Janssen and as part of my compensation I receive stock and options.
    Sponsors:
    I am an employee of J&J / Janssen.
    Patents/Royalties
    I have patents relating to this invention, but do not receive any compensation (e.g. royalties), because of my employment relationship with J&J / Janssen.

Marc Mercken

  • Equity:
    J&J equities/options as employee of J&J
    Sponsors:
    Discovery Research
    Patents/Royalties
    inventor on patents owned by J&J

Setareh H. Moghadam

  • Nothing to Disclose

Randy Slemmon

  • Equity:
    Own JnJ stock
    Sponsors:
    Scientific Director in Janssen Neuroscience Biomarkers

Hong Sun

  • Sponsors:
    I am an employee of Janssen and owns Janssen stocks

Clara Theunis

  • Equity:
    Janssen Pharmaceutica NV stock options.
    Sponsors:
    Scientist at Janssen Pharmaceutica NV

Gallen Triana-Baltzer

  • Equity:
    GTB owns stock in Johnson & Johnson, an affiliate of Janssen R&D.
    Sponsors:
    GTB is an employee of Janssen R&D
    Patents/Royalties
    GTB is author on a patent for the CSF p217+tau assay described in this publication

Kristof Van Kolen

  • Equity:
    RSU
    Sponsors:
    Full-time employee of Janssen Pharmaceutica